N/A N=120 Prospective Feasibility Trial of AccuCath 2.25" Blood Control (BC) Placed in Difficult Access Patients in the Emergency Department
Vascular Access Complication
Primary: First Attempt Success Rate — 92 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=22 Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine
Dengue
Primary: Systemic and Local Reactogenicity Rates for Ungraded Symptoms — 0; 1; 0; 2 Participants
Phase 1 N=16 Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors
Malignancy · Metastasis
Primary: Number of Participants With Adverse Events (AEs) — 3; 7; 6; 1 participants
N/A N=60 Clinical Evaluation of Two Daily Wear Silicon Hydrogel Contact Lens
Myopia
Primary: Visual Acuity — 80; 40 eye
N/A N=305 START-J: SiTAgliptin in eldeRly Trial in Japan
Type 2 Diabetes
Primary: Change From Baseline in HbA1c at 52 W — -0.66; -0.77 percent — p=0.087
N/A N=224 An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: HbA1c at 6 Months — 8.65; 8.75; 8.37; 8.34 percentage of Glycated Haemoglobin — p=0.8222
Phase 2 N=37 ATX-MS-1467 in Multiple Sclerosis
Multiple Sclerosis
Primary: Change From Baseline in the Average Number of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) Over On-treatment Scans — 7.4; -2.4 lesions
N/A N=61 rTMS for Motor and Mood Symptoms of Parkinson's Disease
Parkinson's Disease · Depression
Primary: Motor Subscale of the Unified Parkinson's Disease Rating Scale (UPDRS Part III) — 32.3; 33.1; 32.8; 28.9 units on a scale
Phase 1 N=13 Influence of Bosentan on the Pharmacokinetics of Nintedanib
Healthy
Primary: Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Concentration (AUC0-tz) — 195; 193 nanogram…
N/A N=1,101 Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea
Surveillance
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 19; 1 participants
Phase 2 N=87 Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Secondary Hyperparathyroidism
Primary: Percent Change From Baseline in Mean Pre-hemodialysis Parathyroid Hormone (PTH) During the Efficacy Assessment Phase — 0.3; -19.4; 28.5; -49.4 percent change — p=<0.0001
Phase 2 N=67 Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Activities of Daily Living (ADL) at 18 Months — -11.58; -13.45 units on a scale — p=0.82
Phase 2 N=72 Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
Acute Lymphocytic Leukemia
Primary: Percentage of Participants Reporting Dose Limiting Toxicities (DLTs) During the Phase 1 Dose-Finding Phase — 0; 0; 11.1 Percentage of Participants
Phase 2 N=8 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Cancer · Brain Cancer · Meningioma
Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…
Phase 2 N=262 Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393